Biologics are, mostly, large proteins derived from living organisms or cells and manufactured through a highly complex biotechnological process. Although these drugs are very efficacious, their cost is a major issue for patients and reimbursement agencies. A biosimilar, is the alternative to the original biologic, which shares highly similar, but not identical, safety, and efficacy profiles. Biosimilars may represent a more economical alternative to the costly biological agents already on the market.
07/12/2016 | Tags:
1 of 10